kabutan

D.Western Therapeutics Institute, Inc.(4576) Summary

4576
TSE Growth
D.Western Therapeutics Institute, Inc.
104
JPY
-3
(-2.80%)
Dec 5, 12:44 pm JST
0.67
USD
Dec 4, 10:44 pm EST
Result
PTS
outside of trading hours
103.2
Dec 5, 12:37 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.85
Yield
ー%
Margin Trading Ratio
899.63
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
107 JPY 0.68 USD
Previous Close Dec 4
107 JPY 0.68 USD
High Dec 5, 9:00 am
107 JPY 0.68 USD
Low Dec 5, 10:45 am
103 JPY 0.66 USD
Volume
224,000
Trading Value
0.02B JPY 0.15M USD
VWAP
104.83 JPY 0.68 USD
Minimum Trading Value
10,400 JPY 67 USD
Market Cap
5.64B JPY 0.04B USD
Number of Trades
161
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,164
1-Year High Sep 26, 2025
25,219
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 7,405,400
Nov 21, 2025 0 7,498,800
Nov 14, 2025 0 7,682,700
Nov 7, 2025 0 7,850,300
Oct 31, 2025 0 7,831,300
Company Profile
D.Western Therapeutics Institute, Inc. is a drug discovery venture originating from Mie University, focusing on protein kinase inhibitors and developing glaucoma treatments.
Sector
Pharmaceuticals
D.Western Therapeutics Institute, Inc. conducts research and development of pharmaceuticals in the ophthalmology field, primarily centered on protein kinase inhibitors, and operates a drug discovery business that licenses out its developed products to pharmaceutical companies. Their main product, ripasudil hydrochloride hydrate, has been launched in Japan and Asia as a treatment for glaucoma and ocular hypertension, and is also being developed for expanded use in Fuchs' endothelial corneal dystrophy. Additionally, the ophthalmic surgical aid DW-1002 is currently on sale in Europe and the United States, and is under development in Japan. Clinical trials for their in-house developed product H-1337 are also underway. The company has established an efficient research and development system by utilizing their proprietary Drug Western method and actively collaborating with universities and other companies.